Patients
-
News
TIF Updated Vaccinations & Therapeutic Drugs COVID-19 Guide Has Landed
A comprehensive Guide for both existing and developing vaccines and treatments against COVID-19, exclusively developed by TIF for its global thalassaemia community. Featuring: Pfizer, Moderna, AstraZeneca: What are the differencies…
Read More » -
News
Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy
The U.S. Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for the experimental gene editing therapy GPH101 by Graphite Bio to initiate a Phase 1/2…
Read More » -
News
Blood Supply Challenges & Transfusion Care of Patients With Haemoglobinopathies During COVID-19 Pandemic
The COVID-19 pandemic has had an impact on blood supply in several countries, jeopardizing the already demanding and often suboptimal care for haemoglobinopathies patients, mainly in developing and low-income countries…
Read More » -
News
EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia
The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) has recently approved EdiGene’s application for ET-01, an investigational CRISPR-Cas9 gene editing therapy for patients with transfusion dependent β-thalassaemia. This marks the first…
Read More » -
TIF News
Just Updated: TIF’s Vaccinations & Therapeutic Drugs for COVID-19 Guide
Everything you need to know about the different COVID-19 vaccines, both already available and developing, in one place! Discover our newly updated Guide ”Vaccinations & Therapeutic Drugs for COVID-19”, containing…
Read More » -
TIF News
COVID-19 Vaccines and Haemoglobin Disorders: The Latest Position Statement of the Thalassaemia International Federation
In view of the plans made by national health authorities in every country across the world for the widespread vaccination of individuals against the SARS-CoV-2 virus, the Thalassaemia International Federation…
Read More » -
TIF News
TIF European Thalassaemia & Sickle Cell Disease Symposium To Take Place On 11-13 December 2020
TIF is proudly organising the European Thalassaemia & Sickle Cell Disease Symposium, a joint patients’ and healthcare professionals’ three-day educational event which will take place online on 11 – 13 December…
Read More » -
News
Virtual Conference on Alpha Thalassaemia Major By UCSF on 8-9 January 2021
The Center for Maternal-Fetal Precision Medicine (UCSF) will host a 2-day online international conference on Alpha Thalassaemia Major, which was once considered universally fatal in utero, on 8-9 January 2021. …
Read More » -
News
PK Deficiency Resources Now Available On TIF’s Website
Recognizing the similarities of thalassaemia with other rare anaemias, particularly those affecting red blood cells, (e.g. PKD, SCD), and noting the absence of disease-specific united internationally coordinated patient organizations to…
Read More » -
News
Leave No Patient Behind: A TIF Declaration For Access To Health At The Time of The COVID-19 Pandemic
Download the TIF Declaration HERE
Read More »